Schultes Birgit C 4
4 · Intellia Therapeutics, Inc. · Filed Jan 7, 2026
Insider Transaction Report
Form 4
Schultes Birgit C
EVP, Chief Scientific Officer
Transactions
- Sale
Common Stock
2026-01-05$9.21/sh−8,508$78,359→ 98,533 total
Footnotes (2)
- [F1]Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2026, and does not represent a volitional trade by the Reporting Person.
- [F2]Includes 925 and 932 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on June 30, 2025 and December 31, 2025, respectively.